Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Pharma Execs Urged To Be More Outspoken About Brexit ‘Disaster’

Executive Summary

Pharmaceutical executives from GSK, Sanofi and the UK generic medicines industry body giving evidence on the likely effects of Brexit on the UK life sciences sector at a recent parliamentary committee hearing were asked why they have not been more outspoken about their concerns.

Advertisement

Related Content

Get Full Regulatory Alignment Or See Post-Brexit Declines In Trials, Manufacturing, Product Launches, Says UK Committee
GSK Adds £50m Per Year To Brexit Cost Estimates
Agree A Brexit Transition By March Or See Pharma Waste Money On Contingency Plans, Says UK Cttee
Pharma Lauds Brexit ‘Breakthrough’ But Says Focus Now Must Be On Drug Regulation & Supply

Topics

Advertisement
UsernamePublicRestriction

Register

PS122203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel